Latest Partnerships News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Infragreen Group Ltd has reported a strong FY25 performance, exceeding its prospectus forecasts post-IPO and advancing its footprint in clean energy and waste recovery sectors. The company’s strategic acquisitions and organic growth set the stage for continued momentum into FY26.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

OM Holdings has terminated a previous sale agreement for its 90% stake in OM Materials (Qinzhou) due to buyer issues and entered a new deal to sell 60% to Shaanxi Sinian Metal & Mining, aiming to bolster working capital.

Global Health Limited reports solid progress towards profitability in FY2025, driven by a 6% increase in subscription revenue and strategic AI integration across its healthcare platforms.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

AXP Energy has updated its resource disclosures and is accelerating its gas-to-power strategy to fuel bitcoin mining operations in Oklahoma, leveraging proven oil fields and strong industry partnerships.

Airtasker Limited is set to release its FY25 financial results on 28 August 2025, accompanied by an investor webinar featuring CEO Tim Fung and CFO Mahendra Tharmarajah. The announcement comes as the company highlights its new partnership with the Visa Cash App Racing Bulls Formula One Team.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Ava Group Limited reported solid FY25 results with 5% revenue growth to $31.7 million and a turnaround to positive EBITDA of $2.1 million, underpinned by strong demand for its Aura Ai-X security solutions and a robust $88 million sales pipeline.